Clinical characteristics.

TUBB4A-related neurologic disorders comprise a phenotypic spectrum ranging in onset from infancy to adulthood. An early-infantile presentation is typically associated with hypomyelination, severe stagnation of developmental milestones, encephalopathy, seizures, and hypotonia. A late-infantile presentation is often characterized by acquisition of developmental milestones including walking or supported ambulation with later onset of regression and dystonia. Brain imaging at the time of developmental loss typically identifies hypomyelination. A subset of individuals with late-infantile onset progress to hypomyelination with atrophy of the basal ganglia and cerebellum. Milder presentations are associated with juvenile or adult onset, including a typical adult-onset dystonia characterized as DYT-TUBB4A. Progressive neurologic findings reflect involvement of the pyramidal tracts (spasticity, brisk deep tendon reflexes, and Babinski sign), extrapyramidal system (rigidity, dystonia, choreoathetosis, oculogyric crisis, and perioral dyskinesia), cerebellum (ataxia, intention tremor, dysmetria), and bulbar function (dysarthria, dysphonia, and swallowing). Cognition is variably affected and is usually less severely affected than motor function. The rate of progression varies with disease severity.

Diagnosis/testing.

The diagnosis is established in a proband with characteristic clinical and/or brain MRI findings and a heterozygous TUBB4A pathogenic variant identified by molecular genetic testing.

Management.

Treatment of manifestations: Functionally disabling spasticity may require adaptive equipment (e.g., wheelchairs and walkers) and physical therapy to help prevent secondary injury. Dystonia requires medical management and, when refractory to medical management, possibly surgical intervention. Dysarthria and dysphonia require speech therapy and possible augmentative and alternative communication. Swallowing dysfunction may require gastrostomy tube placement for feeding. Seizures, constipation, cardiac issues, and gastroesophageal reflux disease are treated per standard recommendations.

Surveillance: Routine evaluations of swallowing and feeding to reduce the risk of aspiration; nutritional support to prevent malnutrition; orthopedic assessment to detect musculoskeletal issues including joint dislocations and scoliosis. At least yearly, medical evaluations to assess growth and review medications; evaluations by specialists in occupational therapy, physical therapy, speech therapy, and rehabilitation medicine. Annual neurologic assessment as well as cardiac evaluation to identify related complications.

Genetic counseling.

TUBB4A-related neurologic disorders are inherited in an autosomal dominant manner. Most individuals diagnosed with TUBB4A-related leukodystrophy represent a simplex case (i.e., the only affected family member) and have the disorder as the result of a de novo TUBB4A pathogenic variant or a TUBB4A pathogenic variant inherited from a mosaic, apparently asymptomatic parent. Individuals diagnosed with DYT-TUBB4A usually have the disorder as a result of a pathogenic variant inherited from a parent who may or may not be affected. Each child of an individual with a TUBB4A-related neurologic disorder has a 50% chance of inheriting the TUBB4A pathogenic variant. Once the TUBB4A pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

Suggestive Findings

TUBB4A-related neurologic disorders should be suspected in individuals with the following clinical and brain imaging findings and family history.

Neurologic and neurodevelopmental features variably reported in affected individuals include:

• Neurodevelopmental delays
  • Including motor and speech-language delays
  • Range from mild delays to severe neurodevelopmental impairment with limited acquisition of motor or cognitive milestones
• Abnormal movements including focal, multifocal, or generalized dystonia, with both fixed and mobile features.
  Note: In DYT-TUBB4A, dystonia is typically isolated without additional neurologic features. It may affect all body segments, including the larynx.
• Pyramidal signs including distal spasticity and central hypotonia
  Note: In individuals with milder involvement, this can manifest as spastic diplegia.
• Gait ataxia (due to cerebellar involvement) and dysmetria
• Bulbar involvement
  • Dysarthria, aphonia, or spasmodic dysphonia (seen more commonly in DYT-TUBB4A but may also be seen in earlier forms of hypomyelination with atrophy of the basal ganglia and cerebellum [H-ABC])
  • Dysphagia with feeding difficulties, which can lead to aspiration pneumonia and gastrostomy tube placement
• Cortical visual impairment
• Epilepsy
  • Variable in severity from early to late infantile forms; most often is mild and responsive to anti-seizure medications
  • Developmental and epileptic encephalopathy can occur including severe drug-resistant seizures with hypsarrhythmia including infantile epileptic spasm syndrome evolving into Lennox-Gastaut syndrome

Disease trajectory. Natural history studies have demonstrated different subtypes within the TUBB4A-related leukodystrophy subgroup based on genotype and acquisition of early motor milestones.

• Early infantile: inability to acquire independent sitting by age nine months
• Late infantile: ability to acquire independent sitting by age nine months. Subjects are often able to acquire independent or supported ambulation initially, followed by loss of skills. Within the late infantile subtype, individuals with the recurrent TUBB4A c.745G>A (p.Asp249Asn) pathogenic variant have a predictable and more severe course.
• Juvenile and adult (including DYT-TUBB4A): milder course with gait abnormalities and progressive dystonia

Brain imaging findings. In the earlier-onset forms, a range of white matter abnormalities are seen that are typically hypomyelinating and range from isolated hypomyelination to hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) (see Figure 1). The latter phenotype is characterized by several features:

Figure 1.

MRI findings in individuals with TUBB4A-related leukodystrophy A. Cerebellar white matter T₁-weighted signal that is isointense or mildly hyper- or hypointense relative to gray matter structures; cerebellar atrophy prominently affects the vermis. There (more...)

• Diffuse cerebral hypomyelination manifesting as mild T₂-weighted hyperintensity involving the supratentorial white matter, corpus callosum, and internal capsule, and typically isointense or mildly hyperintense T₁-weighted signal
• Progressive atrophy of the basal ganglia involving predominantly the neostriatum (i.e., the putamen and caudate nucleus), often with a significant decrease in the size of the putamen (which can disappear over time) and to a lesser degree the head of the caudate. The thalamus and globus pallidus are typically spared.
• Although changes in the putamen are evident in many children with the H-ABC phenotype by age two years, in some children the changes may not be evident until later in childhood.
• Cerebellar findings of white matter T₁-weighted signal that is isointense or mildly hyper- or hypointense relative to gray matter structures. Cerebellar atrophy prominently affecting the vermis is a common but not obligatory feature of H-ABC.

In later-onset forms of TUBB4A-related neurologic disorders, brain MRI is often uninformative or non-specific, with more limited white matter abnormalities. In DYT-TUBB4A, brain MRI is typically normal.

Family history. TUBB4A-related neurologic disorders are inherited in an autosomal dominant manner. Childhood-onset TUBB4A-related leukodystrophy is typically caused by a de novo pathogenic variant and most probands represent a simplex case (i.e., a single occurrence in a family); rarely, parental mosaicism may result in multiple affected children. DYT-TUBB4A is inherited in an autosomal dominant manner with multiple family members affected, though reduced penetrance has been reported [Bally et al 2021].

Establishing the Diagnosis

The diagnosis of TUBB4A-related neurologic disorders is established in a proband with characteristic clinical and/or brain MRI findings and a heterozygous TUBB4A pathogenic (or likely pathogenic) variant identified by molecular genetic testing (see Table 1).

Note: (1) Per American College of Medical Genetics and Genomics / Association for Molecular Pathology variant interpretation guidelines, the terms "pathogenic variant" and "likely pathogenic variant" are synonymous in a clinical setting, meaning that both are considered diagnostic and can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variants" in this GeneReview is understood to include likely pathogenic variants. (2) Identification of a heterozygous TUBB4A variant of uncertain significance does not establish or rule out the diagnosis.

Molecular genetic testing approaches can include a combination of gene-targeted testing (multigene panel) and comprehensive genomic testing (exome sequencing, genome sequencing). Gene-targeted testing requires that the clinician determine which gene(s) are likely involved (see Option 1), whereas comprehensive genomic testing does not (see Option 2).

Note: Single-gene testing (sequence analysis of TUBB4A, followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended.

Clinical Description

TUBB4A-related neurologic disorders have a heterogeneous presentation and represent a spectrum of disease. Two primary phenotypes have emerged, TUBB4A-related leukodystrophy and DYT-TUBB4A (previously called DYT4 dystonia).

TUBB4A-related leukodystrophy typically presents in childhood; age of onset ranges from a few months in more severe forms [van der Knaap et al 2002, Gavazzi et al 2025] to later childhood or adulthood in some instances of isolated hypomyelination [Hamilton et al 2014, Pizzino et al 2014, Shimojima et al 2015]. The disorder is progressive and the rate of progression varies with disease severity.

DYT-TUBB4A, formerly known as whispering dysphonia, is a rare cause of isolated dystonia that ranges from mild to severe with onset from early childhood to the third decade of life. While spasmodic dysphonia and/or craniocervical dystonia are often the presenting signs, progression to limbs and/or generalized dystonia is common [Bally et al 2021]. Laryngeal dystonia is the most common feature, present in more than three quarters of affected individuals [Bally et al 2022]. Brain MRI is typically normal.

To date, at least 200 individuals have been identified with a pathogenic variant in TUBB4A [Gavazzi et al 2025]. The following description of the phenotypic features associated with this condition is based on these reports.

Neurodevelopmental delays. Some affected children have a period of normal motor development with subsequent deterioration [van der Knaap et al 2002]. Early- and late-infantile phenotypes have been identified; early-infantile phenotypes associated with inability to acquire developmental milestones, including independent sitting by age nine months, whereas late-infantile phenotypes are characterized by the ability to acquire independent sitting by age nine months [Gavazzi et al 2021]. Individuals with the c.745G>A (p.Asp249Asn) pathogenic variant specifically demonstrate delayed acquisition of developmental milestones [Gavazzi et al 2025]. Cognition is variably affected but usually less severely affected than motor function. Learning difficulties are common; social awareness is usually preserved.

Loss of motor abilities. Loss of independent and supported ambulation, when acquired, is observed in a relevant proportion of affected individuals, with a higher likelihood of occurrence in individuals with the c.745G>A (p.Asp249Asn) pathogenic variant, typically observed after age 8-10 years [Gavazzi et al 2021, Gavazzi et al 2025]. Individuals with the early-infantile form typically acquire very limited milestones such that it is harder to assess loss of milestones.

Pyramidal involvement. Bilateral or unilateral upper motor neuron dysfunction (spasticity, brisk deep tendon reflexes, and Babinski signs) typically manifests in early childhood [Mercimek-Mahmutoglu et al 2005, Wakusawa et al 2006].

Feeding difficulties (including dysphagia). Feeding difficulties emerge over time, necessitating a gastrostomy tube for feeding in most individuals with early-and late-infantile forms. This is more variable in later-onset forms.

Musculoskeletal complications (including scoliosis). Scoliosis is a frequent feature of TUBB4A-related leukodystrophy, sometimes requiring surgical correction.

Cerebellar signs can include ataxia, intention tremor, and dysmetria but are often masked by significant pyramidal dysfunction and movement disorders and may be difficult to quantify. Gait ataxia due to cerebellar involvement can occur.

Basal ganglia involvement due to striatal involvement leads to various movement disorders and includes dystonia, oculogyric crisis, rigidity, choreoathetosis, and perioral dyskinesia. Movement disorders (in particular hemidystonia) can be the first manifestation of TUBB4A-related neurologic disorders. Changes in body position or visual and acoustic stimuli can exacerbate these features.

Dysarthria and dysphonia. Communication and speech difficulties are observed in individuals with TUBB4A-related neurologic disorders over time and across the spectrum. Individuals with early-infantile forms typically do not gain verbal communication, and those with late-infantile presentations may develop aphonia or dysarthria. Dysphonia and dysarthria are typical of later-onset forms, and especially prevalent in DYT-TUBB4A.

Epilepsy. Epilepsy is observed in about 30% of affected individuals overall, with pharmacoresistance in some individuals, in particular individuals with early-infantile onset. In individuals with late-infantile onset and later onset, seizures are infrequent [Gavazzi et al 2025].

Other less common findings (seen in severe cases) include the following [van der Knaap et al 2002, Sasaki et al 2009, Simons et al 2013, Ferreira et al 2014, Hamilton et al 2014]:

• Autonomic dysfunction: postural hypotension, chronic constipation, bladder dysfunction (including urinary retention), excessive sweating (diaphoresis) or impaired sweating (anhidrosis), and abnormalities in temperature regulation
• Microcephaly (congenital or postnatal)
• Short stature
• Poor vision, with possible cortical visual impairment
• Hearing loss
• Cardiovascular involvement has been described in TUBB4A-related leukodystrophy, including aortic dilatation/calcifications, valvular heart defects, arrhythmias, and atrial septal defects [Gavazzi et al 2025].
• Hypogonadotropic hypogonadism (seen in 1 individual) [Tonduti et al 2016]

Neuroimaging studies

• Diffuse cerebral hypomyelination that manifests as mild T₂-weighted hyperintensity involving the supratentorial white matter, corpus callosum, and internal capsule, and typically isointense or mildly hyperintense T₁-weighted signal
• Progressive atrophy of the basal ganglia involving the striatum (i.e., the putamen and caudate nucleus) predominantly, often with a significant decrease in size of the putamen (which can disappear over time) and, to a lesser degree, the head of the caudate. The thalamus and globus pallidus are typically spared. Although changes in the putamen are evident in many children with the hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) phenotype by age two years, in some children the changes may not be evident until later childhood.
• Cerebellar findings of white matter T₁-weighted signal that is isointense or mildly hyper- or hypointense relative to gray matter structures. Cerebellar atrophy prominently affecting the vermis is a common but not obligatory feature of H-ABC.
• Some individuals with a heterozygous TUBB4A pathogenic variant and spastic paraplegia have been described with mild white matter changes on brain MRI [Kancheva et al 2015], thus expanding the spectrum of TUBB4A-related neurologic disorders. To date, however, molecular genetic testing of individuals with as-yet-unclassified hereditary spastic paraplegia has not commonly identified a causative heterozygous TUBB4A pathogenic variant [Kumar et al 2015] (see Differential Diagnosis). Thus, childhood-onset TUBB4A-related neurologic disorder without hypomyelination remains poorly characterized and is an area of active research.

Neurophysiologic studies

• Electroencephalogram is usually normal or demonstrates slow background activity.
• Electromyogram and nerve conduction studies are typically normal.
• Brain stem evoked potentials are usually delayed.
• Visual evoked potentials are usually normal.
• Somatosensory evoked potentials in some instances show delayed conduction [van der Knaap et al 2002].

Genotype-Phenotype Correlations

Several TUBB4A pathogenic variants are consistently associated with specific phenotypes:

• c.1172G>A (p.Arg391His). Individuals with this pathogenic variant have a higher likelihood of presenting with a late-infantile phenotype [Gavazzi et al 2025].
• c.785G>A (p.Arg262His) and c.763G>A (p.Val255Ile). These pathogenic variants have been described in several individuals with hypomyelination without atrophy of the basal ganglia [Ferreira et al 2014, Hamilton et al 2014, Miyatake et al 2014]. Individuals with either of these pathogenic variants have a higher likelihood of presenting with an early-infantile phenotype [Gavazzi et al 2025].
• c.1228G>A (p.Glu410Lys). This pathogenic variant has been described in several individuals with hypomyelination without atrophy of the basal ganglia and have a higher likelihood of presenting with a late-infantile phenotype [Ferreira et al 2014, Hamilton et al 2014, Miyatake et al 2014, Gavazzi et al 2025].
• c.730G>A (p.Gly244Ser). Individuals with this pathogenic variant have a typical H-ABC phenotype and a more severe lack of myelin and a more rapidly progressive disease course [Carvalho et al 2015].
• c.745G>A (p.Asp249Asn). This is the most common recurrent variant and represents about 20% of reported cases to date [Gavazzi et al 2025]. It is very closely associated with the H-ABC phenotype. Individuals with this pathogenic variant demonstrate high rates of acquisition of motor and communication milestones [Gavazzi et al 2021] but demonstrate a higher likelihood of loss of motor milestones in later stages of life [Gavazzi et al 2025].
• Several variants have been described in association with DYT-TUBB4A, including c.4C>G (p.Arg2Gly), c.137G>T (p.Arg46Met), c.361C>T (p.Arg121Trp), c.883G>A (p.Asp295Asn), and c.1272G>C (p.Gln424His) [Hersheson et al 2013, Lohmann et al 2013, Bally et al 2021] (see Table 7).

Penetrance

The penetrance of TUBB4A-related neurologic disorders is not known to date and may differ by phenotypic presentation. Penetrance appears to be 100% in TUBB4A-related leukodystrophy, while there are reports of reduced penetrance in DYT-TUBB4A [Bally et al 2021].

Nomenclature

Because of inconsistencies in the nomenclature of dystonia historically, a naming system that combines the "DYT" designation and the associated gene was proposed by Marras et al [2012] and now follows the recommendations for the Nomenclature of Genetic Movement Disorders by the International Parkinson's Disease and Movement Disorder Society Task Force [Marras et al 2016]. Based on this naming system, DYT4 dystonia / whispering dysphonia is now referred to as DYT-TUBB4A.

Prevalence

The prevalence of TUBB4A-related neurologic disorders is unknown, though more than 200 affected individuals have been reported to date [Gavazzi et al 2025].

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with TUBB4A-related neurologic disorders, the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Treatment of Manifestations

There is no cure for TUBB4A-related neurologic disorders to date. Supportive care to improve quality of life, maximize function, and reduce complications is recommended. This involves longitudinal multidisciplinary care by specialists in relevant fields (see Table 5).

Surveillance

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in Table 6 are recommended.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

See MotherToBaby for further information on medication use during pregnancy.

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Mode of Inheritance

TUBB4A-related neurologic disorders (comprising TUBB4A-related leukodystrophy, DYT-TUBB4A, and other rarer TUBB4A-related phenotypes) are inherited in an autosomal dominant manner.

Risk to Family Members

Parents of a proband

• Most individuals diagnosed with TUBB4A-related leukodystrophy represent a simplex case (i.e., the only affected family member) and have the disorder as the result of a de novo TUBB4A pathogenic variant or a TUBB4A pathogenic variant inherited from a mosaic, apparently asymptomatic parent [Simons et al 2013].
• Individuals diagnosed with DYT-TUBB4A usually have the disorder as a result of a pathogenic variant inherited from a parent who may or may not be affected.
• Other rare TUBB4A-related phenotypes:
  • Transmission of a TUBB4A pathogenic variant from an affected parent to an individual with a complicated hereditary spastic paraplegia phenotype and abnormal brain imaging with hypomyelination in the cerebral cortex was reported in one family [Hsieh et al 2024].
  • Transmission of a TUBB4A pathogenic variant from a mosaic parent to an individual with an epileptic encephalopathy and hypomyelination has been reported [Ben Jdila et al 2023].
• If the proband appears to be the only affected family member (i.e., a simplex case), molecular genetic testing is recommended for the parents of the proband to evaluate their genetic status and inform recurrence risk assessment. Note: A proband may appear to be the only affected family member because of failure to recognize the disorder in family members, reduced penetrance, or early death of a parent before the onset of features. Therefore, de novo occurrence of a TUBB4A pathogenic variant cannot be confirmed unless molecular genetic testing has demonstrated that neither parent is heterozygous for the TUBB4A pathogenic variant.
• If the pathogenic variant identified in the proband is not identified in either parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:
  • The proband has a de novo pathogenic variant.
  • The proband inherited a pathogenic variant from a parent with gonadal (or somatic and gonadal) mosaicism.* Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a pathogenic variant that is present in the germ (gonadal) cells only.
    * A parent with somatic and gonadal mosaicism for a TUBB4A pathogenic variant may be asymptomatic [Simons et al 2013, Ben Jdila et al 2023] or mildly/minimally affected.

Sibs of a proband. The risk to the sibs of the proband depends on the genetic status of the proband's parents:

• If a parent of the proband is affected and/or is known to have the TUBB4A pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.
• If the TUBB4A pathogenic variant identified in the proband cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental gonadal mosaicism. Sib recurrence was reported in a family in which the asymptomatic mother was mosaic for a TUBB4A pathogenic variant [Simons et al 2013].
• If the parents have not been tested for the TUBB4A pathogenic variant but are clinically unaffected, the risk to the sibs of a proband appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for TUBB4A because of the possibility of reduced penetrance in a heterozygous parent and the possibility of parental gonadal mosaicism.

Offspring of a proband. Each child of an individual with a TUBB4A-related neurologic disorder has a 50% chance of inheriting the TUBB4A pathogenic variant.

Other family members. The risk to other family members depends on the status of the proband's parents: if a parent has the TUBB4A pathogenic variant, the parent's family members may be at risk.

Related Genetic Counseling Issues

Family planning

• The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to parents of affected individuals.

Prenatal Testing and Preimplantation Genetic Testing

Once the TUBB4A pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal and preimplantation genetic testing. While most health care professionals would consider use of prenatal and preimplantation genetic testing to be a personal decision, discussion of these issues may be helpful.

Molecular Pathogenesis

TUBB4A encodes the protein tubulin beta-4A chain (TUBB4A), a beta tubulin predominantly expressed in the central nervous system and especially in the cerebellum, putamen, and white matter [Nogales 2001, Hersheson et al 2013]. Beta tubulins bind to alpha tubulins to assemble into microtubules, essential cytoskeleton components with roles in several cellular processes such as mitosis, motility, and transport. Heterozygous TUBB4A pathogenic variants result in changes in beta tubulin structure thought to affect microtubule polymerization or stability [Savage et al 1994].

Mechanism of disease causation. Gain of function

Acknowledgments

The authors would like to acknowledge the contributions of the Global Leukodystrophy Consortium and extend profound thanks to the participants of the Myelin Disorder Bioregistry Project.

Author History

Julien F Bally, MD (2026-present)
Julian Curiel, BS; Children's National Health System (2016-2026)
Alex Conant, BS; Children's National Health System (2016-2026)
Jamie Fraser, MD, PhD (2026-present)
Francesco Gavazzi, MD, PhD (2026-present)
Eline Hamilton, MD; VU University Medical Center (2016-2026)
Norah Nahhas, MD; Children's National Health System (2016-2026)
Amy Pizzino, MS (2026-present)
Cas Simons, PhD (2016-present)
Marjo van der Knaap, MD, PhD (2016-present)
Adeline Vanderver, MD (2016-present)
Nicole I Wolf, MD, PhD (2026-present)

Revision History

• 5 March 2026 (gm) Comprehensive update posted live
• 3 November 2016 (bp) Review posted live
• 2 January 2016 (av) Original submission

Literature Cited

• Bally JF, Camargos S, Oliveira Dos Santos C, Kern DS, Lee T, Pereira da Silva-Junior F, Puga RD, Cardoso F, Barbosa ER, Yadav R, Ozelius LJ, de Carvalho Aguiar P, Lang AE. DYT-TUBB4A (DYT4 dystonia): new clinical and genetic observations. Neurology. 2021;96:e1887-e1897. [PMC free article: PMC8105968] [PubMed: 32943487]
• Bally JF, Kern DS, Fearon C, Camargos S, Pereira da Silva-Junior F, Barbosa ER, Ozelius LJ, de Carvalho Aguiar P, Lang AE. DYT-TUBB4A (DYT4 dystonia): clinical anthology of 11 cases and systematized review. Mov Disord Clin Pract. 2022;9:659-75. [PMC free article: PMC9274350] [PubMed: 35844288]
• Ben Jdila M, Kammoun F, Abdelmaksoud-Dammak R, Triki C, Fakhfakh F. Mutation in the β-tubulin gene TUBB4A results in epileptic encephalopathy associated with hypomyelinated leucodystrophy: Unexpected findings reveal genetic mosaicism. Int J Dev Neurosci. 2023;83:532-45. [PubMed: 37529938]
• Carvalho D, Santos S, Martins B, Marques FP. TUBB4A novel mutation reinforces the genotype-phenotype correlation of hypomyelination with atrophy of the basal ganglia and cerebellum. Brain. 2015;138:e327. [PubMed: 25168210]
• Delorme C, Roze E, Karachi C, Vidailhet M, Hainque E. Whispering dysphonia in TUBB4A-related disorders responsive to bipallidal deep brain stimulation. Eur J Neurol. 2021;28:1082-1083. [PubMed: 33084096]
• Ferreira C, Poretti A, Cohen J, Hamosh A, Naidu S. Novel TUBB4A mutations and expansion of the neuroimaging phenotype of hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). Am J Med Genet A. 2014;164A:1802-7. [PMC free article: PMC10506160] [PubMed: 24706558]
• Gavazzi F, Charsar B, Hamilton E, Erler JA, Patel V, Woidill S, Sevagamoorthy A, Helman G, Schmidt J, Pizzino A, Muirhead K, Takanohashi A, Bonkowsky JL, Meyerhoffer K, Simons C, Doi H, Satoko M, Matsumoto N, Delgado MR, Sanchez-Castillo M, Wang J, de Carvalho DR, Tournev I, Chamova T, Jordanova A, Clegg NJ, Nicita F, Bertini E, Teng M, Williams D, Tonduti D, Houlden H, Stellingwerff M, Wassmer E, Garcia-Cazorla A, Bernard G, Mirchi A, Toutounchi H, Wolf NI, van der Knaap MS, Shults J, Adang LA, Vanderver AL. The natural history of variable subtypes in pediatric-onset TUBB4A-related leukodystrophy. Mol Genet Metab. 2025;144:109048. [PMC free article: PMC11875891] [PubMed: 39951964]
• Gavazzi F, Charsar BA, Williams C, Shults J, Alves CA, Adang L, Vanderver A. Acquisition of developmental milestones in hypomyelination with atrophy of the basal ganglia and cerebellum and other TUBB4A-related leukoencephalopathy. J Child Neurol. 2021;36:805-11. [PMC free article: PMC8505576] [PubMed: 34514881]
• Hamilton EM, Polder E, Vanderver A, Naidu S, Schiffmann R, Fisher K, Raguž AB, Blumkin L; H-ABC Research Group, van Berkel CG, Waisfisz Q, Simons C, Taft RJ, Abbink TE, Wolf NI, van der Knaap MS. Hypomyelination with atrophy of the basal ganglia and cerebellum: further delineation of the phenotype and genotype-phenotype correlation. Brain. 2014;137:1921-30. [PMC free article: PMC4345790] [PubMed: 24785942]
• Hersheson J, Mencacci NE, Davis M, MacDonald N, Trabzuni D, Ryten M, Pittman A, Paudel R, Kara E, Fawcett K, Plagnol V, Bhatia KP, Medlar AJ, Stanescu HC, Hardy J, Kleta R, Wood NW, Houlden H. Mutations in the autoregulatory domain of β-tubulin 4a cause hereditary dystonia. Ann Neurol. 2013;73:546-53. [PMC free article: PMC3698699] [PubMed: 23424103]
• Hsieh PC, Yu PS, Fan WL, Wang CC, Chao CY, Wu YR. A new phenotype of TUBB4A mutation in a family with adult-onset progressive spastic paraplegia and isolated hypomyelination leukodystrophy: a case report and literature review. J Mov Disord. 2024;17:94-8. [PMC free article: PMC10846974] [PubMed: 37867417]
• Kancheva D, Chamova T, Guergueltcheva V, Mitev V, Azmanov DN, Kalaydjieva L, Tournev I, Jordanova A. Mosaic dominant TUBB4A mutation in an inbred family with complicated hereditary spastic paraplegia. Mov Disord. 2015;30:854-8. [PubMed: 25772097]
• Kumar KR, Vulinovic F, Lohmann K, Park JS, Schaake S, Sue CM, Klein C. Mutations in TUBB4A and spastic paraplegia. Mov Disord. 2015;30:1857-8. [PubMed: 26477786]
• Lohmann K, Wilcox RA, Winkler S, Ramirez A, Rakovic A, Park JS, Arns B, Lohnau T, Groen J, Kasten M, Brüggemann N, Hagenah J, Schmidt A, Kaiser FJ, Kumar KR, Zschiedrich K, Alvarez-Fischer D, Altenmüller E, Ferbert A, Lang AE, Münchau A, Kostic V, Simonyan K, Agzarian M, Ozelius LJ, Langeveld AP, Sue CM, Tijssen MA, Klein C. Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol. 2013;73:537-45. [PMC free article: PMC6956988] [PubMed: 23595291]
• Marras C, Lang A, van de Warrenburg BP, Sue CM, Tabrizi SJ, Bertram L, Mercimek-Mahmutoglu S, Ebrahimi-Fakhari D, Warner TT, Durr A, Assmann B, Lohmann K, Kostic V, Klein C. Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. Mov Disord. 2016;31:436-57 [PubMed: 27079681]
• Marras C, Lohmann K, Lang A, Klein C. Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. Neurology. 2012;78:1016-24. [PMC free article: PMC3310311] [PubMed: 22454269]
• Mercimek-Mahmutoglu S, van der Knaap MS, Baric I, Prayer D, Stoeckler-Ipsiroglu S. Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). Report of a new case. Neuropediatrics. 2005;36:223-6. [PubMed: 15944912]
• Miyatake S, Osaka H, Shiina M, Sasaki M, Takanashi J, Haginoya K, Wada T, Morimoto M, Ando N, Ikuta Y, Nakashima M, Tsurusaki Y, Miyake N, Ogata K, Matsumoto N, Saitsu H. Expanding the phenotypic spectrum of TUBB4A-associated hypomyelinating leukoencephalopathies. Neurology. 2014;82:2230-7. [PubMed: 24850488]
• Murala S, Nagarajan E, Bollu PC. Hereditary spastic paraplegia. Neurol Sci. 2021 Mar;42(3):883-894. [PubMed: 33439395]
• Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct. 2001;30:397-420. [PubMed: 11441808]
• Pizzino A, Pierson TM, Guo Y, Helman G, Fortini S, Guerrero K, Saitta S, Murphy JL, Padiath Q, Xie Y, Hakonarson H, Xu X, Funari T, Fox M, Taft RJ, van der Knaap MS, Bernard G, Schiffmann R, Simons C, Vanderver A. TUBB4A de novo mutations cause isolated hypomyelination. Neurology. 2014;83:898-902. [PMC free article: PMC4153852] [PubMed: 25085639]
• Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24. [PMC free article: PMC4544753] [PubMed: 25741868]
• Sasaki M, Takanashi J, Tada H, Sakuma H, Furushima W, Sato N. Diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum. Brain Dev. 2009;31:582-7. [PubMed: 18851904]
• Savage C, Xue Y, Mitani S, Hall D, Zakhary R, Chalfie M. Mutations in the Caenorhabditis elegans beta-tubulin gene mec-7: effects on microtubule assembly and stability and on tubulin autoregulation. J Cell Sci. 1994;107:2165-75. [PubMed: 7983175]
• Shimojima K, Okumura A, Ikeno M, Nishimura A, Saito A, Saitsu H, Matsumoto N, Yamamoto T. A de novo TUBB4A mutation in a patient with hypomyelination mimicking Pelizaeus-Merzbacher disease. Brain Dev. 2015;37:281-5. [PubMed: 24974158]
• Simons C, Wolf NI, McNeil N, Caldovic L, Devaney JM, Takanohashi A, Crawford J, Ru K, Grimmond SM, Miller D, Tonduti D, Schmidt JL, Chudnow RS, van Coster R, Lagae L, Kisler J, Sperner J, van der Knaap MS, Schiffmann R, Taft RJ, Vanderver A. A de novo mutation in the β-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am J Hum Genet. 2013;92:767-73. [PMC free article: PMC3644625] [PubMed: 23582646]
• Tonduti D, Aiello C, Renaldo F, Dorboz I, Saaman S, Rodriguez D, Fettah H, Elmaleh M, Biancheri R, Barresi S, Boccone L, Orcesi S, Pichiecchio A, Zangaglia R, Maurey H, Rossi A, Boespflug-Tanguy O, Bertini E. TUBB4A-related hypomyelinating leukodystrophy: New insights from a series of 12 patients. Eur J Paediatr Neurol. 2016;20:323-30. [PubMed: 26643067]
• van der Knaap MS, Naidu S, Pouwels PJ, Bonavita S, van Coster R, Lagae L, Sperner J, Surtees R, Schiffmann R, Valk J. New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. AJNR Am J Neuroradiol. 2002;23:1466-74. [PMC free article: PMC7976795] [PubMed: 12372733]
• Wakusawa K, Haginoya K, Kitamura T, Togashi N, Ishitobi M, Yokoyama H, Higano S, Onuma A, Nara T, Iinuma K. Effective treatment with levodopa and carbidopa for hypomyelination with atrophy of the basal ganglia and cerebellum. Tohoku J Exp Med. 2006;209:163-7. [PubMed: 16707859]